High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Rachner, Tilman D ^a   Thiele, Stefanie ^a   Göbel, Andy ^a   Browne, Andrew ^a   Fuessel, Susanne ^a   Erdmann, Kati ^a   Wirth, Manfred P ^a   Fröhner, Michael ^a   Todenhöfer, Tilman ^b   Muders, Michael H ^a   Kieslinger, Matthias ^c   Rauner, Martina ^a   Hofbauer, Lorenz C ^a,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

DKK 1; Prognosis; Prostate cancer

Indexed keywords

DICKKOPF 1 PROTEIN; DKK1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TISSUE MICROARRAY; BLOOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL;

AGED; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907415671     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-649     Document Type: Article

References (16)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594. 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G, 9362426.
2. Daoussis D, Andonopoulos AP. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodelling?. Semin Arthritis Rheum 2011, 41:170-177. 10.1016/j.semarthrit.2011.01.006, 21435697.
3. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643. 10.1210/en.2007-0270, 17395698.
4. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494. 10.1056/NEJMoa030847, 14695408.
5. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P, Garnero P. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007, 97:964-970. 2360424, 17876334.
6. Rachner TD, Göbel A, Thiele S, Rauner M, Benad-Mehner P, Hadji P, Bauer T, Muders MH, Baretton GB, Jakob F, Ebert R, Bornhäuser M, Schem C, Hofbauer LC. Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Res 2014, in press.
7. Rachner TD, Göbel A, Benad-Mehner P, Hofbauer LC, Rauner M. Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Lett 2014, 346:172-177. 10.1016/j.canlet.2014.01.010, 24462802.
8. Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumour to metastasis. Prostate 2008, 68:1396-1404. 10.1002/pros.20805, 3260942, 18561248.
9. Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate 2011, 71:615-625. 10.1002/pros.21277, 3025080, 20957670.
10. Hall CL, Zhang H, Baile S, Ljungman M, Kuhstoss S, Keller ET. p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Res 2010, 70:9916-9926. 10.1158/0008-5472.CAN-10-0440, 3059079, 21098705.
11. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013, 123:4918-4922. 10.1172/JCI70354, 3809798, 24135135.
12. Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A. Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?. Int J Mol Sci 2013, 14:11816-11829. 10.3390/ijms140611816, 3709757, 23736690.
13. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114:371-379. 10.1182/blood-2008-11-191577, 2714212, 19417213.
14. Krause U, Ryan DM, Clough BH, Gregory CA. An unexpected role for a Wnt-inhibitor: Dickkopf-1 triggers a novel cancer survival mechanism through modulation of aldehyde-dehydrogenase-1 activity. Cell Death Dis 2014, 27:e1093.
15. Dong LL, Qu LY, Chu LY, Zhang XH, Liu YH. Serum level of DKK-1 and its prognostic potential in non-small cell lung cancer. Diagn Pathol 2014, 9:52. 10.1186/1746-1596-9-52, 3975329, 24612589.
16. Jiang T, Huang L, Zhang S. DKK-1 in serum as a clinical and prognostic factor in patients with cervical cancer. Int J Biol Markers 2013, 28:221-225. 10.5301/jbm.5000005, 23595579.